Laura Perin, Ph.D., Co-Director of the GOFARR Laboratory at The Saban Research Institute of Children's Hospital Los Angeles, along with Valter Longo, Ph.D., Professor at USC Longevity Institute of the Davis School of Gerontology, and international collaborators conducted a study that is offering promising results.

In the study, they fed animal models with chronic kidney disease a specialized low-salt, fasting-mimicking diet (LS-FMD) equivalent to the recommended daily intake for human patients with chronic kidney disease.

The study is published in the journal Science Translational Medicine.

Study calls into question the feasibility of assessment of the risk for sudden cardiac death as basis for a personalised decision on preventive defibrillator implantation  

Hallak et al have found that intact SARS-CoV-2 virions can “hide” in a population of sperm for months after COVID-19 infection. A study of 13 patients admitted to the Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil, with moderate to severe COVID-19 showed that male gametes released extracellular viral traps (in a process called ETosis).

The findings underscore the potential role of Lp(a) as an important prognostic marker and suggest that incorporating Lp(a) assessment into clinical practice could enhance risk stratification.

New research suggests older adults wait 3-6 months after a heart attack before elective noncardiac surgery to reduce the risk of serious complications like stroke or another heart attack.

Women with known or suspected sleep apnea were more likely than men to have symptoms or a diagnosis of dementia at every age level

The CLEAR SYNERGY (OASIS 9) clinical trial explored both the short- and long-term use of colchicine in patients who undergo percutaneous coronary intervention (PCI) after an AMI. From 2018 to 2022, more than 7,000 patients from 14 different countries were randomized within 72 hours of PCI to undergo treatment with colchicine or a placebo.

Overall, after a median follow-up period of three years, the study’s primary endpoint—a composite of cardiovascular death, recurrent myocardial infarction, stroke or ischemia-driven revascularization—was not significantly improved for patients treated with colchicine (9.1%) compared to those treated with the placebo (9.3%). 

This randomized clinical trial showed that vitamin K₂ supplementation significantly reduced the frequency, intensity, and duration of NLCs in an older population with good safety.